Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hydrocodone extended-release - Teva Pharmaceutical Industries

Next Previous
X
Search
Drug Profile

Hydrocodone extended-release - Teva Pharmaceutical Industries

Alternative Names: CEP-33237; Hydrocodone bitartrate extended-release - Teva; Tamper-deterrent hydrocodone; Twice-daily hydrocodone - Teva; VANTRELAER

Latest Information Update: 08 Jan 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cephalon
  • Developer Teva Pharmaceutical Industries
  • Class Antitussives; Morphinans; Opioid analgesics; Opioid peptides; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Pain

Most Recent Events

  • 12 Dec 2017 Hydrocodone extended-release tablets is still at registered stage for Pain in USA (PO) (Teva pharma website, December 2017)
  • 18 Jan 2017 Registered for Pain in USA (PO) - First global approval
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Pain in Canada (PO, Controlled release)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top